[18F]FDG-6-P as a novel in vivo tool for imaging staphylococcal infections
Background Management of infection is a major clinical problem. Staphylococcus aureus is a Gram-positive bacterium which colonises approximately one third of the adult human population. Staphylococcal infections can be life-threatening and are frequently complicated by multi-antibiotic resistant str...
Gespeichert in:
Veröffentlicht in: | EJNMMI research 2015-03, Vol.5 (1), p.13-13, Article 13 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background
Management of infection is a major clinical problem.
Staphylococcus aureus
is a Gram-positive bacterium which colonises approximately one third of the adult human population. Staphylococcal infections can be life-threatening and are frequently complicated by multi-antibiotic resistant strains including methicillin-resistant
S. aureus
(MRSA). Fluorodeoxyglucose ([
18
F]FDG) imaging has been used to identify infection sites; however, it is unable to distinguish between sterile inflammation and bacterial load. We have modified [
18
F]FDG by phosphorylation, producing [
18
F]FDG-6-P to facilitate specific uptake and accumulation by
S. aureus
through hexose phosphate transporters, which are not present in mammalian cell membranes. This approach leads to the specific uptake of the radiopharmaceutical into the bacteria and not the sites of sterile inflammation.
Methods
[
18
F]FDG-6-P was synthesised from [
18
F]FDG. Yield, purity and stability were confirmed by RP-HPLC and iTLC. The specificity of [
18
F]FDG-6-P for the bacterial universal hexose phosphate transporter (UHPT) was confirmed with S.
aureus
and mammalian cell assays
in vitro
. Whole body biodistribution and accumulation of [
18
F]FDG-6-P at the sites of bioluminescent staphylococcal infection were established in a murine foreign body infection model.
Results
In vitro
validation assays demonstrated that [
18
F]FDG-6-P was stable and specifically transported into
S. aureus
but not mammalian cells. [
18
F]FDG-6-P was elevated at the sites of
S. aureus
infection
in vivo
compared to uninfected controls; however, the increase in signal was not significant and unexpectedly, the whole-body biodistribution of [
18
F]FDG-6-P was similar to that of [
18
F]FDG.
Conclusions
Despite conclusive
in vitro
validation, [
18
F]FDG-6-P did not behave as predicted
in vivo
. However at the site of known infection, [
18
F]FDG-6-P levels were elevated compared with uninfected controls, providing a higher signal-to-noise ratio. The bacterial UHPT can transport hexose phosphates other than glucose, and therefore alternative sugars may show differential biodistribution and provide a means for specific bacterial detection. |
---|---|
ISSN: | 2191-219X 2191-219X |
DOI: | 10.1186/s13550-015-0095-1 |